Comparative Analysis of Image Quality and Adverse Events between Iopamidol 250 and Ioversol 320 in Hepatic Angiography for Transcatheter Arterial Chemoembolization
10.3348/jksr.2020.81.1.166
- Author:
Min Jae GU
1
;
Jae Hyuck YI
;
Young Hwan KIM
;
Hee Jung LEE
;
Ung Rae KANG
;
Seung Woo JI
Author Information
1. Department of Radiology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. yijh7@naver.com
- Publication Type:Original Article
- From:Journal of the Korean Radiological Society
2020;81(1):166-175
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE:This study aimed to compare the image quality and adverse events between Iopamidol 250 and Ioversol 320 usage during transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
MATERIALS AND METHODS:Medical records and hepatic angiography from 113 patients who underwent TACE with Iopamidol 250 (44 patients) and Ioversol 320 (69 patients) were retrospectively reviewed. Vessel perception on hepatic angiography was graded into three categories by two radiologists for hepatic subsegmental arteries, the right gastroepiploic artery, right gastric artery, and pancreaticoduodenal artery. Imaging concordance was assessed by comparing the number of detected HCCs on hepatic angiography and CT. The adverse events before and after hepatic angiography were evaluated.
RESULTS:The mean vessel perception scores were 2.92 and 2.94 for Iopamidol 250 and Ioversol 320, respectively. The imaging concordance was 31 (70.5%) and 46 (66.7%) patients for Iopamidol 250 and Ioversol 320, respectively. There were no statistical differences in vessel perception or imaging concordance (p > 0.05). One and six patients experienced nausea for Iopamidol 250 and Ioversol 320, respectively. There was no statistical difference in adverse events (p = 0.24).
CONCLUSION:Iopamidol 250 can be used in hepatic angiography for TACE without significant difference in image quality or occurrence of adverse events from Ioversol 320.
